The 2024 ESC GLs on Hypertension are here! Key updates: New BP category: "Elevated BP" (120-139/70-89 mmHg) - Target systolic BP: 120-129 mmHg (if tolerated)-Focus on CVD outcomes over BP reduction alone-Personalized treatment #ESCCongress2024#hypertension
We are proud to recognize PEERLESS II as our 3rd #RCT in #VTE. Across #PEERLESS & #PEERLESSII, Inari is now set to enroll over 1700 #PE RCT patients.
Thank you to the PEERLESS II Global PIs for your partnership & dedication to generating high quality clinical evidence: @jaygirimd, @FMaeWestMD, @FelixMahfoud, & Prof Bernhard Gebauer.
@aerztezeitung@DGK_org@Saar_Uni Important information for all patients with #hypertension. High amount of hidden sodium in effervescent-tablet dietary supplements and OTC drugs. Patients at risk should be advised to limit effervescent tablets. @BMJ_Open https://t.co/xAcmNudqWJ @Herzmedizin_de
Brausetabletten enthalten große Mengen an #Natrium und könnten daher #Hypertonie-Kranke gefährden, warnen Kardiologen @DGK_org. Sie fordern eine Kennzeichnungspflicht auf Verpackungen. Zitiert wird auch @FelixMahfoud von der @Saar_Uni. #Kardiologie
https://t.co/Np9j0yoMke
Der Universitätsrat hat @mertz_kirsten zur Professorin für Allgemeine Pathologie sowie @FelixMahfoud zum Professor für Kardiologie gewählt.
👉 https://t.co/7IQxXlCATD
🔉The new Impact Factor of EuroIntervention is 6.2.
This achievement places the journal once again in the top quartile among cardiovascular publications and solidifies our position as the second-ranked subspecialty journal in interventional cardiology. Thank you to all!
This statement of the @escardio Council on Hypertension and the #EAPCI reviews the evidence on renal denervation and provides consensus statements for patient selection, centre requirements, procedural aspects, and considerations for trial design.
https://t.co/4EiXl61aTq